Day One Biopharmaceuticals (DAWN) News Today → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free DAWN Stock Alerts $16.00 -0.38 (-2.32%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Moderate Buy" by Analystsamericanbankingnews.com - May 12 at 1:14 AMQ2 2024 Earnings Estimate for Day One Biopharmaceuticals, Inc. Issued By Wedbush (NASDAQ:DAWN)americanbankingnews.com - May 11 at 2:29 AMDay One Biopharmaceuticals, Inc. Forecasted to Post Q2 2024 Earnings of ($0.75) Per Share (NASDAQ:DAWN)marketbeat.com - May 10 at 7:37 AMFY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Decreased by Analystamericanbankingnews.com - May 10 at 4:16 AMDay One Biopharmaceuticals, Inc. to Post Q3 2024 Earnings of ($0.69) Per Share, HC Wainwright Forecasts (NASDAQ:DAWN)americanbankingnews.com - May 10 at 3:32 AMCapital One Financial Comments on Day One Biopharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:DAWN)americanbankingnews.com - May 10 at 2:16 AMFY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Lowered by Analystmarketbeat.com - May 9 at 8:23 AMTimesSquare Capital Management LLC Has $24.33 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)marketbeat.com - May 9 at 12:57 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Given "Outperform" Rating at Wedbushamericanbankingnews.com - May 8 at 6:24 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLCamericanbankingnews.com - May 8 at 5:52 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $40.00 Price Target at HC Wainwrightamericanbankingnews.com - May 8 at 5:52 AMBuy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market Entrymarkets.businessinsider.com - May 8 at 1:18 AMBuy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic Commercializationmarkets.businessinsider.com - May 8 at 1:18 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Given Outperform Rating at Wedbushmarketbeat.com - May 7 at 3:06 PMDay One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate Progressfinanznachrichten.de - May 7 at 10:16 AMIndegene IPO subscribed 7.34 times on Day 2msn.com - May 7 at 10:16 AMHC Wainwright Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $40.00marketbeat.com - May 7 at 8:32 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down Following Insider Sellingamericanbankingnews.com - May 7 at 1:34 AMDay One Reports First Quarter 2024 Financial Results and Corporate Progressglobenewswire.com - May 6 at 4:30 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down on Insider Sellingmarketbeat.com - May 6 at 10:36 AMJeremy Bender Sells 9,154 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stockamericanbankingnews.com - May 5 at 6:50 AMCharles N. York II Sells 8,078 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stockamericanbankingnews.com - May 5 at 5:42 AMCharles N. York II Sells 52,183 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stockamericanbankingnews.com - May 5 at 5:10 AMJeremy Bender Sells 70,051 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stockamericanbankingnews.com - May 5 at 4:38 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 8,078 Sharesinsidertrades.com - May 4 at 8:09 AMInsider Sale at Day One Biopharmaceuticals Inc (DAWN)finance.yahoo.com - May 4 at 4:22 AMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $144,192.30 in Stockmarketbeat.com - May 3 at 9:03 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 52-Week High at $17.87marketbeat.com - May 1 at 3:50 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 5.2% Higher marketbeat.com - April 29 at 1:56 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 10.9%marketbeat.com - April 25 at 6:17 PMDay One slips despite Ojemda approval as BofA says label “not a home run”msn.com - April 24 at 7:17 PMDay One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fairseekingalpha.com - April 24 at 2:15 PMDay One Biopharmaceuticals' (DAWN) "Outperform" Rating Reiterated at Wedbushmarketbeat.com - April 24 at 2:13 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase Following Analyst Upgrademarketbeat.com - April 24 at 11:01 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $33.00 at Needham & Company LLCmarketbeat.com - April 24 at 7:29 AMBuy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospectsmarkets.businessinsider.com - April 23 at 11:13 PMBuy Rating Affirmed for Day One Biopharmaceuticals Following FDA Approval of Ojemdamarkets.businessinsider.com - April 23 at 11:13 PMDay One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumorfinance.yahoo.com - April 23 at 6:12 PMDay One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumorglobenewswire.com - April 23 at 3:56 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 12.2% on Analyst Upgrademarketbeat.com - April 23 at 2:37 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Sharesinsidertrades.com - April 23 at 4:24 AMBuy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impactmarkets.businessinsider.com - April 22 at 10:07 PMInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 10,000 Shares of Stockmarketbeat.com - April 22 at 9:20 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Analyst Upgrademarketbeat.com - April 22 at 11:39 AMDay One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00 at JPMorgan Chase & Co.marketbeat.com - April 22 at 11:00 AMDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.7% marketbeat.com - April 19 at 2:56 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Sees Strong Trading Volumemarketbeat.com - April 18 at 4:55 PMAnalysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)markets.businessinsider.com - April 16 at 6:18 PMDay One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% Higher marketbeat.com - April 16 at 2:01 PMDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 6.6% in Marchmarketbeat.com - April 16 at 1:40 PM Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (Ad)Join us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. Click here to register now (5/15 Webinar) DAWN Media Mentions By Week DAWN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.160.58▲Average Medical News Sentiment DAWN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼423▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Xencor News Today Morphic News Today Protagonist Therapeutics News Today Akero Therapeutics News Today Dynavax Technologies News Today Kiniksa Pharmaceuticals News Today Arcus Biosciences News Today ANI Pharmaceuticals News Today Taro Pharmaceutical Industries News Today Kura Oncology News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
